White matter hyperintensities and cerebral amyloidosis: Necessary and sufficient for clinical expression of Alzheimer disease?

JAMA Neurology

Volumn 70, Issue 4, 2013, Pages 455-461

  Provenzano, Frank A ^a,b   Muraskin, Jordan ^a,b   Tosto, Giuseppe ^a   Narkhede, Atul ^a   Wasserman, Ben T ^a   Griffith, Erica Y ^a   Guzman, Vanessa A ^a   Meier, Irene B ^a   Zimmerman, Molly E ^c   Brickman, Adam M ^a  

^a NewYork Presbyterian Hospital   (United States)

^b Fu Foundation School of Engineering and Applied Sciences Columbia University ^*  (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RISK FACTOR; WHITE MATTER HYPERINTENSITY;

EID: 84876144291     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.1321     Document Type: Article

References (49)

1. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.
2. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319. (Pubitemid 38269583)
3. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-1725. (Pubitemid 46763260)
4. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129-135.
5. Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009;21(1):117-128.
6. Sojkova J, Resnick SM. In vivo human amyloid imaging. Curr Alzheimer Res. 2011;8(4):366-372.
7. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45(3):358-368. (Pubitemid 29120041)
8. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837-1844. (Pubitemid 44049813)
9. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509-1517.
10. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452. (Pubitemid 44214969)
11. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106(16):6820-6825.
12. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131(pt 3):665-680. (Pubitemid 351294719)
13. Lockhart A, Lamb JR, Osredkar T, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130(pt 10):2607-2615. (Pubitemid 47511709)
14. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated β-amyloid deposition in elderly subjects. Brain. 2009;132(pt 5):1310-1323.
15. Rodrigue KM, Kennedy KM, Devous MD, et al. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78(6):387-395.
16. Bourgeat P, Chételat G, Villemagne VL, et al; AIBL Research Group. Betaamyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010;74(2):121-127.
17. Hedden T, Van Dijk KR, Becker JA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29(40):12686-12694.
18. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130(pt 11):2837-2844. (Pubitemid 350033975)
19. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10(9):819-828.
20. Altman R, Rutledge JC. The vascular contribution to Alzheimer's disease. Clin Sci (Lond). 2010;119(10):407-421.
21. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
22. Yoshita M, Fletcher E, Harvey D, et al. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology. 2006;67(12):2192-2198. (Pubitemid 46035476)
23. Luchsinger JA, Brickman AM, Reitz C, et al. Subclinical cerebrovascular disease in mild cognitive impairment. Neurology. 2009;73(6):450-456.
24. Brickman AM, Provenzano FA, Muraskin J, et al. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community [published online September 3, 2012]. Arch Neurol. doi:10.1001/archneurol.2012.1527.
25. Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol. 2004;61(10):1531-1534. (Pubitemid 39350263)
26. Brickman AM, Honig LS, Scarmeas N, et al. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol. 2008;65(9):1202-1208.
27. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7(5):486-488. (Pubitemid 10073130)
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944. (Pubitemid 14076461)
29. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983;17(1):37-49. (Pubitemid 13123113)
30. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201-209.
31. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528-1547. (Pubitemid 41541962)
32. Jack CR Jr, Lowe VJ, Weigand SD, et al; Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132(pt 5):1355-1365.
33. Muraskin J, Provenzano FA, Brickman AM. Fully Automatic White Matter Hyperintensity Segmentation Without FLAIR. Montreal, Canada: Human Brain Mapping; 2011.
34. Admiraal-Behloul F, Olofesen H, Van den Heuvel DM, Schmitz N, Reiber JH, Van Buchem MA. Fully automated lobe delineation for regional white matter lesion load quantification in a large scale study. Proc Int Soc Magn Reson Med. 2004:138.
35. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23(suppl 1):S208-S219. (Pubitemid 39421720)
36. Brickman AM, Schupf N, Manly JJ, et al. Brainmorphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. Arch Neurol. 2008;65(8):1053-1061.
37. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001;20(1):45-57. (Pubitemid 32293419)
38. Mamdani EH, Assilian S. An experiment in linguistic synthesis with a fuzzy logic controller. Int J Man Mach Stud. 1975;7(1):1-13. doi:10.1016/S0020-7373 (75) 80002-2.
39. Takagi T, Sugeno M. Fuzzy identification of systems and its applications to modeling and control. IEEE Trans Syst Man Cybern. 1985; SMC-15(1):116-132. doi: 10.1109/TSMC.1985.6313399.
40. Manolio TA, Kronmal RA, Burke GL, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults: The Cardiovascular Health Study. Stroke. 1994;25(2):318-327. (Pubitemid 24047252)
41. de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study: The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry. 2001;70(1):9-14. (Pubitemid 32096113)
42. Liao D, Cooper L, Cai J, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control: The ARIC Study: Atherosclerosis Risk in Communities Study. Stroke. 1996;27(12):2262-2270. (Pubitemid 26427203)
43. Liao D, Cooper L, Cai J, et al. The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC Study. Neuroepidemiology. 1997;16(3):149-162. (Pubitemid 27215864)
44. De Carli C, Miller BL, Swan GE, et al. Predictors of brain morphology for the men of the NHLBI twin study. Stroke. 1999;30(3):529-536. (Pubitemid 29115387)
45. Brickman AM, Reitz C, Luchsinger JA, et al. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol. 2010;67(5):564-569.
46. Gunning-Dixon FM, Brickman AM, Cheng JC, Alexopoulos GS. Aging of cerebral white matter: a review of MRI findings. Int J Geriatr Psychiatry. 2008;24(2):109-117.
47. Gorelick PB, Scuteri A, Black SE, et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-2713.
48. Brickman AM, Muraskin J, Zimmerman ME. Structural neuroimaging in Altheimer's disease: do white matter hyperintensities matter? Dialogues Clin Neurosci. 2009;11(2):181-190.
49. Stenset V, Johnsen L, Kocot D, et al. Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42. Neurology. 2006;67(5):830-833. (Pubitemid 44394198)